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Abstract: 
Human African trypanosomiasis (HAT) is a parasitic disease, caused by the protozoan pathogen 
Trypanosoma brucei, which affects thousands every year and which is in need of new therapeutics. 
Herein we report the synthesis and assessment of a series of pyrrolidine and pyrazolone derivatives of 
human phosphodiesterase 4 (hPDE4) inhibitors for the assessment of their activity against the 
trypanosomal phosphodiesterase TbrPDEB1. The synthesized compounds showed weak potency against 
TbrPDEB1. 
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Human African trypanosomiasis (HAT), or African sleeping sickness, is a parasitic disease caused by the 
protozoan pathogen Trypanosoma brucei. HAT is predominantly found in poor, remote rural regions of 
sub-Saharan Africa. Currently, over 60 million people in 36 countries in sub-Saharan Africa are at risk, 
with approximately 10,000 infections annually.
1
 HAT is a neglected tropical disease (NTD), in that 
relatively little attention has been paid to finding new treatments. 
Four drugs are approved for the treatment of HAT: pentamidine, suramin, eflornithine, and melarsoprol. 
The nifurtimox–eflornithine combination therapy (NECT) has also been approved for HAT which 
provides safety and dosing advantages over eflornithine monotherapy.
2, 3
 Though effective, these drugs 
are limited by serious and sometimes lethal side effects, inconvenient route of administration and 
increasing incidence of drug resistance.
3, 4
 Considering the economic and social burden that HAT 
produces, further work is needed in finding safe and effective drugs that are safer, simpler to administer 
and cheaper than those currently available. With this in mind, our research efforts have been directed 
towards repurposing established classes of inhibitors of druggable human targets to be inhibitors of 
essential parasite targets.
5
 Phosphodiesterases (PDEs) are a family of enzymes that regulate signal 
transduction mediated by cAMP and cGMP in the cell, and inhibition of these enzymes reduces cAMP or 
cGMP PDE degradation, thus affecting the physiological processes controlled by these second 
messengers. Numerous PDE inhibitors are used as therapeutics.
6
 Trypanosoma brucei expresses ﬁve 
PDEs, two of which, TbrPDEB1 and TbrPDEB2, have together been shown by RNAi to be essential for 
parasite proliferation.
7
 The catalytic domains of human PDEs share 30–35% sequence identity to those of 
the parasite enzymes TbrPDEB1 and TbrPDEB2,
8
 thus we reasoned that human PDE inhibitors 
repurposing could be a useful approach. We tested a range of human PDE (hPDE) inhibitors against 
TbrPDEB1 and B2, and we observed that the hPDE4 inhibitor piclamilast (1, Figure 1) inhibits both 
TbrPDEB1 and B2 and T. brucei brucei (Tbb) cell growth in vitro.
9
 Cilomilast (2), another 
commercialized hPDE4 inhibitor, and some of its analogs, have been found to inhibit TbrPDEB1.
10
 We 
observed the prototypical hPDE4 inhibitor rolipram (3) to be inactive against TbrPDEB1. 
  
Another class of human PDE4 phthalizinones has also been pursued, leading to the discovery of 
compound 4, which is the most active TbrPDEB1/B2 inhibitor to date (IC50 3.98 nM and 6.0 nM 
respectively for TbrPDEB1 and B2).
11
 The related phtalazininone compound 5 shows an IC50 of 278 nM 
against TbrPDEB1.
12
 In addition, pyrazolone 6 was identified through a scaffold merging approach.
13
 
Despite the obvious structural similarity between compounds 1-3, 5 and 6, their reported TbrPDEB1 IC50 
values fall in a wide range. These molecules share the cyclopentyl-substituted catechol functionality, and 
differ in the region of the molecule (highlighted in red) pointing towards the catalytic metals in the 
binding site region. This suggested to us that this “headgroup” region must be a major driver of potency 
against TbrPDEB1. With this in mind, in this letter we report our attempt to find novel TbrPDEB1 
inhibitors driven by the replacement of the pyrrolidinone moiety of compound 3 with different five-
membered rings. 
As a starting point, we prepared racemic trans-3,4-disubstituted pyrrolidine analogues as an intended 
mimic of the pyrazolinone headgroup of 4 (Scheme 1). The sequence was initiated with Wittig olefination 
of aldehyde 8 to obtain the phenylacrylic acid ester 9. Iminium ylide cycloaddition of compound 9 with 
sarcosine and formaldehyde in refluxing toluene gave the corresponding trans-3,4-disubstituted N-methyl 
pyrrolidine ethyl ester 10a.
14
 A small library of amides (compounds 11a-k) has been prepared starting 
from the ester 10a by reaction with the corresponding aluminum amide, while LiOH hydrolysis of ester 
10a gave the corresponding acid 10b. Demethylation of 10a with 1-chloroethyl chloroformate produced 
the pyrrolidine 12,
15
 which was converted to compounds 13a and 13b with methanesulfonyl chloride or 
acetyl chloride, respectively. Compounds 10, 11 and 13 were all found to be weak inhibitors of 
TbrPDEB1 (Table 1). 
We then prepared two pyrazolone-based inhibitors (compounds 18a and 18b), as shown in Scheme 2. 
Acid 14 was converted to the corresponding acyl chloride with thionyl chloride and reacted with the 
lithium enolate of methyl acetate to provide 16. The β-keto-ester intermediate 16 was cyclized to the 
desired pyrazolol derivative 18a using hydrazine hydrochloride in refluxing acetic acid. Compound 18a 
  
was alkylated with bromocyclopentane to obtain compound 18b. Compounds 18a-b were also found to 
have little activity against TbrPDEB1 (Table 2). 
We looked towards increasing the size of the headgroup region, looking to mimic the size and shape of 
compounds 4-7 more closely, and therefore prepared the spirocyclic compounds 21a-d (Scheme 2). The 
β-keto-ester 16 was first alkylated with 1,5-diiodopentane to give compound 19 which cyclized to 21a 
when treated with hydrazine. This could be N-alkylated with various alkyl bromides to give compounds 
21b-d.  
Besides preparing the cyclopentyl-substituted catechol analogs, we noted that improved T brucei cellular 
potency had been reported for 7 (Tbb EC50: 6.3 μM) when compared to 6 (>64 μM).
13
 Thus, we prepared 
the benzyl-substituted analogs 22a-d. Compounds 21 and 22 were tested against TbrPDEB1 (Table 3), 
and, despite the structural similarity these compounds and the known actives 6 and 7, we found that these 
analogs had very little ability to inhibit TbrPDEB1. We can conclude, based on this and on our previous 
attempts to explore structural variations around compound 1 that the SAR is extraordinarily tight for this 
class of compounds.
9, 12
 With this in mind, our efforts are focused on obtaining a better understanding of 
the subtle structural features needed for an optimal enzyme inhibition. 
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Table 1. rac-(trans-3,4)-Disubstituted pyrrolidine analogs tested against TbrPDEB1 
 
 
Cpd R R1 TbrPDEB1 (% inh)
a
 
10a OCH2CH3 CH3 8 ± 11 
10b OH CH3 17 ± 9 
11a 
 
CH3 5 ± 5
c
 
11b 
 
CH3 7 ± 5
c
 
11c 
 
CH3 8 ± 0 
11d 
 
CH3 6 ± 6 
11e 
 
CH3 16 ± 11 
11f 
 
CH3 10 ± 5 
11g 
 
CH3 16 ± 6 
11h NHCH3 CH3 8 ± 0 
11i NHCH2CH3 CH3 5 ± 4  
11j 
 
CH3 1 ± 2 
11k 
 
CH3 10 ± 3 
13a OCH2CH3 SO2CH3 3 ± 4 
13b OCH2CH3 COCH3 15 ± 0 
a
Data shown are average of 2 replicate independent experiments. Compounds were tested at 10 µM 
concentrations. 
b
n=1 
c 
Replicate of 3 independent experiments. 
 
  
  
Table 2. Pyrazololo analogs tested against TbrPDEB1 
 
 
Cpd R R1 TbrPDEB1 (% inh)
a
 
18a 
 
H 0 
18b 
  
5 ± 3  
a
Data shown are average of 2 replicate independent experiments. Compounds were tested at 10 µM 
concentrations. 
 
 
  
  
Table 3. Spiro pyrazolone analogs tested against TbrPDEB1 
 
 
Cpd R R1 TbrPDEB1 (% inh)
a
 
21a 
 
H 11 ± 10 
21b 
  
18 ± 2 
21c 
 
 
9 ± 4
b
 
21d 
 
 
9 ± 6
b
 
22a 
 
H 14 ± 20 
22b 
 
 
11 ±10
b
 
22c 
  
7 ± 5 
22d 
  
10 ± 3 
a
Data shown are average of 2 replicate independent experiments. Compounds were tested at 10 µM 
concentrations. 
b 
Replicate of 3 independent experiments. 
 
 
 
  
 
Figure 1. Compounds previously studied as TbrPDEB1 inhibitors.  
  
  
 
Scheme 1. Synthesis of pyrrolidine derivatives. Reagents and conditions: (a) (Carbethoxymethylene)triphenylphosphorane, 
CH3CN, MW, 150 °C, 20 min; (b) formaldehyde, sarcosine, MgSO4, toluene, 170 °C, 24 h; (c) LiOH, H2O, MeOH, THF, rt, 2 h; 
(d) appropriate amine, Me3Al, Toluene, 80 °C, 12 h; (e) i. 1-Chloroethyl chloroformate, DMAP, 1,2-dichloroethane, reflux, 
overnight; ii. MeOH, reflux 4h; (f) acetyl chloride or methanesulfonyl chloride, DMAP, DMF, rt, overnight. 
  
 
Scheme 2. Synthesis of pyrazolone derivatives. Reagents and conditions: (a) SOCl2, DMF, 90 °C, 3 h; (b) MeOAc, LDA, THF, -
78 °C then rt, 1 h; (c) 1,5-diiodopentane, K2CO3, DMF, 90 °C, overnight; (d) hydrazine hydrochloride, acetic acid, 120 °C, 2 h; 
(e) hydrazine hydrochloride, DIPEA, BuOH, 120 °C, 3 h; (f) alkyl bromide, K2CO3, DMF, 70 °C, 2 h; (g) NaH, alkyl bromide, 
DMF, 60 °C, 3 h. 
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